Two batches of a common constipation medicine have been recalled. Patients do not need to stop taking it
What happened
On 5 October 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall for two batches of MOVICOL Plain 13.7g powder for oral solution. The medicine is made by Norgine Limited. The recall notice is numbered EL(26)A/41. MOVICOL Plain is a very common medicine. It is a macrogol laxative, used to treat constipation. It comes as a powder in a sachet. You stir the powder into water and drink it. Many people take it for weeks or months at a time, and it is used by children as well as adults. Two batches are affected: - Batch 487069, with an expiry date of 28 February 2029. This batch was distributed from 5 June 2026. - Batch 474919, with an expiry date of 31 August 2028. This batch was distributed from 7 November 2025. The reason given is that some units contain the incorrect amounts of active ingredients. In plain terms, a small number of sachets may not hold the right dose of the medicine. The MHRA has classed this as a Class 3 recall. That is important, and we explain what it means below. Pharmacies, dispensing doctors and wholesalers have been told to stop supplying the two batches straight away, to put any remaining stock to one side, and to return it to their supplier. The advice for patients is different. If you already have a pack from one of these batches at home, you do not need to do anything. The MHRA says you can carry on taking it.
Why this matters
Recalls sound frightening. The word itself suggests something has gone badly wrong. But most medicine recalls in the UK are not emergencies, and this one is a good example of the system working quietly in the background. MOVICOL Plain is used by a lot of people, including some who find it hard to manage without it. Constipation is not a minor thing if you are frail, recovering from surgery, taking strong painkillers, or living with a long-term condition. So a recall on a medicine like this reaches a large number of households at once. That is exactly why the difference between the advice for pharmacies and the advice for patients matters so much. If people hear the word recall and stop taking their laxative, some of them will become unwell. Stopping suddenly can undo weeks of careful progress. The MHRA has not asked anyone to stop. There is also a wider point. Britain's medicine safety system depends on thousands of pharmacy teams reading these notices and acting on them, usually within days, usually without anyone noticing. Most patients will never hear about this recall at all, because their pharmacy will simply have quietly swapped the stock before their next prescription is dispensed.
What the evidence actually says
The MHRA sorts medicine recalls into classes, and the class tells you how serious the risk is thought to be. A Class 1 recall is the most serious. It means the problem could cause death or serious harm, and action is needed immediately. A Class 2 recall means the problem could cause illness or harm that is usually not life-threatening, and action is needed within 48 hours. A Class 3 recall, which is what this is, means the defect is unlikely to cause harm. Action is needed within five days. Class 3 recalls are usually about quality, not danger. So what does an incorrect amount of active ingredient mean here? Macrogol laxatives work by holding water in the bowel, which softens the stool and makes it easier to pass. The dose is not knife-edge. If one sachet in a pack holds a little more or a little less powder than it should, the likely result is that the medicine works slightly better or slightly less well on that day. That is why the MHRA has told patients to keep using their packs rather than return them. The notice also tells anyone who thinks they have had a side effect to report it through the MHRA's Yellow Card scheme. Yellow Card is open to the public, not just to doctors and pharmacists. It is one of the main ways the regulator spots problems with medicines in the first place, and reports from ordinary patients genuinely do get read.
Qurexa perspective
We deliver prescriptions, so recall notices like this one land on our desk as practical work rather than news. The honest picture is that recalls are routine. The MHRA publishes drug alerts most weeks. Pharmacy teams across the country check the batch numbers against their shelves, pull anything affected, and carry on. It is unglamorous and it is one of the reasons the UK medicines supply is as safe as it is. If you are a Qurexa customer and you take MOVICOL Plain, there is nothing for you to do. If a batch we have supplied is affected, we handle the stock side of it. Your supply continues. The one thing we would ask is this: if you ever get a letter or a leaflet in with your medicines that you do not understand, ring and ask. Pharmacists would much rather spend two minutes explaining a notice than have somebody stop a medicine they need because a word on a page looked alarming.
Practical advice
If you take MOVICOL Plain 13.7g sachets: - Keep taking it as prescribed. The MHRA has not asked patients to stop or to return their packs. - You can check your box if you want to. The batch number is usually printed on the end flap or the side of the carton, often next to the expiry date. The two batches in this recall are 487069 and 474919. - Even if your pack is from one of those batches, the advice is still to continue using it. - If you feel the medicine is not working as well as usual, or your constipation is getting worse, speak to your pharmacist. They can check the dose and suggest adjustments. - If you think you have had a side effect from any medicine, you can report it yourself at the Yellow Card website. You do not need a doctor to do it for you. - Norgine's medical information team can be reached on 01895 826606 if you have questions about the product itself. For pharmacies, dispensing doctors and wholesalers, the notice asks you to stop supplying the two batches immediately, quarantine remaining stock, and return it through your usual supplier route. One more general point, because it comes up a lot: constipation that is new, painful, or comes with bleeding, weight loss or vomiting is worth a same-week conversation with your GP or pharmacist. Laxatives are a treatment, not an answer to the question of why it started.
What to know
The MHRA recalled two batches of MOVICOL Plain 13.7g sachets on 5 October 2026, because some sachets may hold the wrong amount of active ingredient. The batches are 487069 and 474919. Pharmacies and wholesalers must stop supplying them and return stock within five days. Patients do not need to stop taking the medicine and do not need to return packs they already have. This is a Class 3 recall, the least serious of the MHRA's three classes, meaning the defect is unlikely to cause harm. If your laxative does not seem to be working properly, talk to your pharmacist rather than simply stopping it. Sources: MHRA / GOV.UK, 'Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41', 5 October 2026, https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-norgine-limited-movicol-plain-13-dot-7g-powder-for-oral-solution-el-26-a-slash-41 ; MHRA, 'Yellow Card scheme', https://yellowcard.mhra.gov.uk/ ; GOV.UK, 'Medicines and Healthcare products Regulatory Agency', https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Do not start or stop any medicine on the strength of a news article.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…